Agilent Technologies Collaborates with Wasatch BioLabs to Transform Multi-Omic Analysis
- Agilent Technologies partners with Wasatch BioLabs to promote the Direct Targeted Methylation Sequencing (dTMS) platform for enhanced genomic analysis.
- The collaboration combines Agilent's enrichment chemistries with WBL's native-read workflow for improved multi-omic analysis in research and clinical settings.
- Agilent aims to enhance customer experience and streamline access to next-generation sequencing data through joint educational programs and technology demonstrations.
Agilent Technologies Partners with Wasatch BioLabs to Enhance Multi-Omic Analysis
Agilent Technologies announces a significant collaboration with Wasatch BioLabs (WBL) through a co-marketing agreement aimed at promoting WBL's Direct Targeted Methylation Sequencing (dTMS) platform. This partnership merges Agilent's advanced enrichment chemistries, namely SureSelect and Avida, with WBL's proprietary Oxford Nanopore-based native-read workflow. The integration of these technologies is poised to revolutionize targeted multi-omic analysis, making it more accessible for both research use only (RUO) and clinical applications. By enabling precise targeting of genomic regions up to 1 megabase while preserving critical DNA characteristics, this collaboration addresses the limitations often encountered with conventional sequencing methods.
The innovative approach facilitated by this partnership is particularly relevant for liquid biopsy and targeted genomic applications. As the demand for precise and cost-effective sequencing solutions grows, the dTMS platform stands out for its ability to analyze structural variations and methylation patterns effectively. Dean Lilley, Senior Director of Product Development at WBL, underscores the significance of multi-omic biology in advancing our understanding of diseases. He emphasizes that this collaboration with Agilent not only enhances the reliability of native-read targeted sequencing but also fosters reproducibility in research efforts. Early adopters in various fields, including oncology, neurology, and prenatal research, are already leveraging the dTMS platform for more informed decision-making in their studies.
Agilent's commitment to innovation is further reflected in the strategic plans outlined in the agreement. The two companies intend to jointly deliver scientific content, educational programs, and technology demonstrations up to 2027, aiming to enhance the customer experience and streamline access to high-quality next-generation sequencing (NGS) data. Nina Green, Agilent's Vice President and General Manager of Clinical Diagnostics, highlights that this partnership not only enables the provision of innovative solutions but also offers operational flexibility, ultimately benefiting researchers and clinicians alike. By improving turnaround times for genomic insights across diverse research areas, the collaboration positions both companies as leaders in advancing genomic analysis technology.
Related Cashu News

Bristol-Myers Squibb's Reclassification Enhances Growth Potential in Defensive Investment Strategy
Bristol-Myers Squibb Company (Ticker: BMY) undergoes a key reclassification across the Russell indexes, marking a transformative moment for the company. Moving to the Russell 1000 Defensive and Russel…

Vertex Pharmaceuticals' Casgevy Gains FDA Approval for Expanded Sickle Cell Disease Treatment Options
Vertex Pharmaceuticals (Ticker: VRTX) receives a significant boost in its ongoing battle against sickle cell disease with the recent FDA approval of an expanded label for its gene therapy product, Cas…

Gilead Sciences Gains FDA Approval for Trodelvy in First-Line Triple-Negative Breast Cancer Treatment
Gilead Sciences (Ticker: GILD) makes significant strides in oncology therapy with the recent approval of its drug Trodelvy for patients with unresectable or metastatic triple-negative breast cancer. T…

Merck Advances HIV Treatment and Faces Regulatory Scrutiny Amidst Market Success
Merck & Co. (Ticker: MRK) has recently made significant strides in the pharmaceutical landscape, particularly with its advancements in HIV treatment. The company's innovative drug, IDVYNSO, has receiv…

